News|Articles|October 1, 2025

Q4 2025 FDA Preview: 10 Decisions to Watch

Fact checked by: Abigail Brooks, MA, Victoria Johnson

Explore key FDA decisions in Q4 2025, impacting treatments for atopic dermatitis, chronic rhinosinusitis, and rare diseases.

The first 3 quarters of 2025 have already been historic for many in medicine, with the US Food and Drug Administration (FDA) clearing the way for new therapies in C3 glomerulopathy, IgG4-related disease, recessive dystrophic epidermolysis bullosa, and even granting the first twice-yearly HIV prevention option.¹